Patient information
Please see Sup. Table 1 for patient and cohort information. Blast counts per sample across technologies are reported in Sup. Table 10.
TuPro / AML
a multi-omic functional and molecular tumor profiling study.
This page relates to the paper Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia by Rebekka Wegmann et al. Please cite this paper and acknowledge the consortium when using these resources.
The study profiled a total of 57 samples from 21 patients with relapsed/refractory acute myeloid leukemia (rr-AML), using up to 7 distinct OMICs platforms on each sample. Please also see the detailed descriptions of the supplementary tables.
Datasets
Single-cell RNA-sequencing
Summary scRNA-seq data is available at Zenodo. Raw data at European Genome-Phenome Archive (EGA). Bulkified AML data in Sup. Data 6.
Single-cell proteomics (CyTOF)
CyTOF data is available at Zenodo. See Sup. Data 14 for antibody details. Bulkified AML data in Sup. Data 7.
Pharmacoscopy
Please see Sup. Data 9 for ex vivo drug screening results. Sup. Data 12 provides details on the used compounds.
Bulk RNA Sequencing
Raw bulk RNA sequencing data are available at the European Genome-Phenome Archive (EGA). Summary data is reported in Sup. Data 4.
Single-cell DNA Sequencing
Raw scDNA-sequencing data are available at the European Genome-Phenome Archive (EGA). Derived copy number alterations are reported in Sup. Data 3.
Bulk proteomics
Raw proteomics data are available at MassIVE. Summary data is reported in Sup. Data 5.
Mutational profiling
Mutational profiling by Foundation One Heme is available at Sup. Data 2.